Books and Book Chapters

      How to build your multiorgan-on-a-chip system: a case study

      Bovard, D.; Sandoz, A.
      Date published
      Nov 15, 2019
      DOI
      10.1016/B978-0-12-817202-5.00015-2
      ISBN
      978-0-12-817202-5
      Published in
      Organ-on-a-chip: Engineered Microenvironments for Safety and Efficacy Testing
      Editors
      Hoeng, J.; Bovard, D.; Peitsch, M. C.
      Link to publication
      Topic
      Summary

      Organ-on-a-chip (OOC) and multiorgan-on-a-chip (MOC) devices combine one or several cellular models with an engineered microenvironment. In the last 5 years, this technology has been demonstrated to improve cell resemblance with the in vivo situation to a level never reached before. Developing this platform can, therefore, be attractive to laboratories, but because this field combines two different fields of expertise, biology and engineering, it requires good project planning and excellent communication between people from the two fields. This chapter provides a guide for the thought process behind the development of an OOC or MOC platform to help laboratories construct their fit-for-purpose chip. This guide largely mirrors the rationale and developmental aspects used to develop a functional lung/liver-on-a-chip system in our laboratory, which will be used as a case study to assist readers in developing their chip.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.